| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 500mg |
|
Purity: ≥98%
AMG-25 (AMG25) is a novel, oral, potent and selective inhibitor of c-Kit with anticancer activity and desirable pharmacokinetic properties. It inhibits c-Kit with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively.
| ln Vitro |
Compound 25, also known as c-Kit-IN-5, has selectivity against KDR, p38, Lck, and Src that is more than 200 times higher (IC50=>5.0, 40, 7.8, and >5.0 μM, respectively)[1].
|
|---|---|
| ln Vivo |
c-Kit-IN-5 (compound 25) (1 mg/kg; iv) demonstrates CL (0.46 L/h/kg) and Vdss (1.59 L/kg) in rats[1]. c-Kit-IN-5 (10 mg/kg; po) demonstrates AUC0-t(9860 ng·h/mL) Cmax(1230 ng/mL), T1/2 (2.6 h), and F (39%) in rats[1].
|
| References |
| Molecular Formula |
C23H17N5O2EXACTMASS
|
|---|---|
| Molecular Weight |
395.4134
|
| Exact Mass |
395.138
|
| CAS # |
1003311-62-3
|
| PubChem CID |
24879368
|
| Appearance |
Light yellow to light brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
720.7±70.0 °C at 760 mmHg
|
| Flash Point |
389.7±35.7 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.709
|
| LogP |
2.78
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
714
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IGFSMGCBFTXTJK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H17N5O2/c1-14-8-10-28(18-5-2-15(3-6-18)21-25-9-11-30-21)22(29)20(14)16-4-7-19-17(12-16)13-26-23(24)27-19/h2-13H,1H3,(H2,24,26,27)
|
| Chemical Name |
3-(2-aminoquinazolin-6-yl)-4-methyl-1-[4-(1,3-oxazol-2-yl)phenyl]pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~63.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.67 mg/mL (4.22 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.67 mg/mL (4.22 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5290 mL | 12.6451 mL | 25.2902 mL | |
| 5 mM | 0.5058 mL | 2.5290 mL | 5.0580 mL | |
| 10 mM | 0.2529 mL | 1.2645 mL | 2.5290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA